A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”

on Behalf of the EORTC PAMM Group

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of preclinical drug-discovery phases and target validation.
Original languageEnglish
Pages (from-to)3413-3418
JournalAnticancer Research
Volume39
Issue number7
DOIs
Publication statusPublished - 2019

Cite this

@article{e49b253020d44f3bbea46abbf4c3ba2c,
title = "A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”",
abstract = "One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of preclinical drug-discovery phases and target validation.",
author = "{on Behalf of the EORTC PAMM Group} and Mjriam Capula and Cristina Corno and Hassouni, {Btissame E. L.} and Petri, {Giovanna L. I.} and Sandra Aranđelović",
year = "2019",
doi = "10.21873/anticanres.13485",
language = "English",
volume = "39",
pages = "3413--3418",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”. / on Behalf of the EORTC PAMM Group.

In: Anticancer Research, Vol. 39, No. 7, 2019, p. 3413-3418.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - A brief guide to performing pharmacological studies in vitro: Reflections from the EORTC-PAMM Course “Preclinical and Early-phase Clinical Pharmacology”

AU - on Behalf of the EORTC PAMM Group

AU - Capula, Mjriam

AU - Corno, Cristina

AU - Hassouni, Btissame E. L.

AU - Petri, Giovanna L. I.

AU - Aranđelović, Sandra

PY - 2019

Y1 - 2019

N2 - One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of preclinical drug-discovery phases and target validation.

AB - One aim of cell-based in vitro assays is to identify the best drug candidate to develop using the best tumor cell model. This is challenging in every anticancer drug discovery process. Briefly, we summarize the parameters to be taken into account when performing in vitro cell assays, in order to obtain reliable and reproducible results, which was fundamentally discussed by lecturers at the educational course on preclinical and early-phase clinical pharmacology studies, at the 40th Winter Meeting of the Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. Moreover, specific cellular sensitivity tests are described. In addition to monolayer in vitro cell models for the screening of new potential candidate drugs, three-dimensional tumor/cell tissue models are emerging as new pre-clinical tools that more closely reflect the in vivo microenvironment. Therefore, the use of different in vitro models for drug screening can enhance the predictability and reliability of preclinical drug-discovery phases and target validation.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85068256711&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31262863

U2 - 10.21873/anticanres.13485

DO - 10.21873/anticanres.13485

M3 - Review article

VL - 39

SP - 3413

EP - 3418

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -